NCT02035657View on ClinicalTrials.gov

A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Merkel Cell Carcinoma
Interventions
BIOLOGICAL

GLA-SE

Glucopyranosyl Lipid A in Stable Emulsion

Trial Locations (1)

98109

University of Washington Medical Center, Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
lead

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02035657 - A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | Biotech Hunter | Biotech Hunter